^
Association details:
| Biomarker: | FGFR4 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Published date:
08/05/2023
Excerpt:
We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1-4 alterations...an objective response was observed in 64 (30% [95% CI 24-36]) of 217 patients across 16 distinct tumour types... RAGNAR results show clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options.
DOI:
10.1016/S1470-2045(23)00275-9
Trial ID:
